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Anti-Müllerian hormone (AMH) is a glycoprotein produced by the gonads and a member of the trans-
forming growth factor superfamily, similar to inhibins. 
Previously, this hormone was referred to as Müllerian-
inhibiting substance, known for its pivotal role in male 
embryonic sexual differentiation. More recent studies 
using female AMH knock-out mice convincingly eluci-
dated its crucial role in the recruitment of follicles from 
the resting primordial pool resulting in premature fol-
licle exhaustion (1).
Initial human studies suggested that AMH could in-
deed be used as a marker of the remaining functional 
ovarian reserve (2). The study by de Vet et al was re-
cently elected as 1 of 25 seminal papers by the American 
Society of Reproductive Medicine, emphasizing the key 
significance of ovarian aging in current infertility care 
(2). The key questions remain, however, as to what ex-
tent the amount of growth of AMH-producing follicles 
truly represents the size of the remaining resting prim-
ordial follicle pool and whether this is constant across 
the life course. Direct counting of the number of fol-
licles present in human ovaries is not feasible. A more 
practical approach would be to assess whether single 
or repeat measurements of AMH concentrations at a 
younger age is associated with the age of menopause, 
a state of terminal follicular depletion, later in life. This 
would provide indirect proof that the size of the group 
of developing follicles is indeed a direct representation 
of the remaining resting follicle pool.
It is well established that both natural and assisted 
conception pregnancy rates decline significantly with 
increasing female age (3). However, the 100-fold differ-
ence in follicle count that can be observed in 2 women 
of the same age, which unsurprisingly covers the wide 
age range of 40 to 60 years of menopause, renders age 
per se of limited value as a marker of ovarian reserve. To 
be able to use AMH as a robust biomarker of ovarian 
aging would be of great clinical significance, but—not 
surprisingly—life is not that simple.
A recent individual patient data meta-analysis pub-
lished in this journal involving measurements of AMH 
at a single time-point in 7 cross-sectional cohorts and 
a total of 2,596 women of whom 1,077 already experi-
enced menopause concluded that AMH was associated 
with time to menopause with low precision, and any 
improvement above age alone was restricted to those 
women with an early menopause before 45 years (4). It is 
to be expected that repeated AMH measurements in lon-
gitudinal studies, accounting for the individual’s trajec-
tory of decline, may improve precision. The analysis of a 
Dutch population cohort of 2,434 women followed every 
5 years for a total of 20 years concluded that knowledge 
of the individual AMH decline rates did not improve the 
prediction of menopause for women above the age of 
25 years (4). In contrast, the Penn Ovarian Aging Study 
involving 293 women with 2 measures of AMH over a 
14-year follow-up did suggest that the rate of decline was 
an independent predictor of time to menopause (5). These 
findings are in accordance with the study by Therani and 
colleagues (this issue). The authors report a prospective 
cohort study of 959 reproductive aged women, with 
follow-up twice after initial screening with an average 
interval of 6 years between measurements. After a total 
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of 14 years follow-up, 529 (55%) reached menopause. 
The authors concluded that the model’s discrimination 
adequacy, as assessed by C-statistic, increased from 0.70 
(95% confidence interval 0.67, 0.71) for a single AMH 
assessment to 0.78 (95% confidence interval 0.75, 0.80) 
for repeated measurement; the median difference be-
tween actual and predicted age of menopause decreased 
from −0.48 to −0.21 years, respectively. Whether these 
opposing findings between studies reflect different popu-
lations studied, differences in the frequency of follow-up, 
or differences in the methodology for ascertainment of 
AMH concentration remains unclear, but notably none 
of these studies have confirmed the predictive validity of 
the derived models in an external population.
AMH is currently being used in clinical practice as a 
marker for ovarian aging in a great variety of conditions, 
such as the early diagnosis of premature ovarian insuf-
ficiency, assessing the extent of ovarian damage due to 
chemotherapy or surgery, assessing of chances of spon-
taneous pregnancy in women with the desire to have 
children now or later (which may also be relevant for 
a decision to freeze oocytes for later use), assessment 
of ovarian responsiveness to stimulation to allow indi-
vidualization of the extent of ovarian stimulation for in 
vitro fertilization, and, finally, assessment of chances of 
pregnancy in “infertile” women of more advanced repro-
ductive age relevant for making decisions about the most 
appropriate treatment option, which may also include 
the use of donor oocytes. In addition, AMH is being in-
tensely studied as a potential diagnostic marker of poly-
cystic ovary syndrome to potentially replace the need to 
assess ovarian morphology by transvaginal ultrasound.
The application of AMH assays to routine clinical 
practice has been problematic (6). Although robust re-
producible automated assays with good technical per-
formance are readily available currently, older, less 
sensitive manual enzyme-linked immunosorbent assays, 
known to exhibit substantial variation and require steps 
to deal with complement interference, are still frequently 
reported. Even the modern assays do not have equiva-
lent calibration, rendering their interpretation assay-
specific. Clinical interpretation is also fraught with 
difficulty as factors that alter folliculogenesis (such as 
steroid contraceptive pill use) or ethnic differences may 
influence AMH concentrations (7). Lastly, for long-term 
prediction, even mild fluctuations across and between 
menstrual cycles may impact on accuracy.
In summary, the accurate prediction of age of menopause 
for a given woman at younger age would be exciting, both 
in the context of distinct individual variation in the onset of 
decreased fertility along with the age of menopause related 
long-term general health risks such as well-being, osteoporosis, 
breast cancer, and cardiovascular health. Whether predictive 
potential may improve further by combining AMH concen-
trations with single nucleotide polymorphism patterns asso-
ciated with age of menopause warrants further investigation. 
At present, prior to clinical adoption, clarification of the gen-
eralizability of models, including its use in different ethnic 
populations, and determination of whether measurement at 
a young enough age with adequate precision to inform re-
productive choices is feasible remain critical.
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